unique treatment
component1

HyQvia®: The only once-a-month* SCIG with Recombinant Human Hyaluronidase (Hy)1

The hyaluronidase in HyQvia locally, temporarily, and reversibly modifies the hyaluronan in the subcutaneous tissue, helping increase the dispersion and absorption of IG into the bloodstream, so your patients can receive a full monthly* dose of IG subcutaneously.

*Every 3 or 4 weeks.

Over the course of the efficacy and extension trials of HyQvia in ~3.5 years (2959 infusions), there were no clinically observable changes in the skin or the subcutaneous tissue. Permeability of the subcutaneous tissue is restored within 24 to 48 hours.

How hyaluronidase works

  • HyQvia was studied in a prospective, open-label, noncontrolled, multicenter clinical trial conducted to determine the efficacy, tolerability, and pharmacokinetics (PK) of HyQvia in patients with primary immunodeficiency (PI). The primary outcome measure was the annualized rate of acute serious bacterial infections (ASBIs), which was evaluated in 83 patients over a median treatment duration of 366 days (42 to 507 days)
  • 66 subjects who completed the efficacy clinical trial enrolled in a prospective, open-label, multicenter extension trial to assess the long-term safety and tolerability of HyQvia. The cumulative exposure of HyQvia across the two trials was 188 subject-years and 2959 infusions, and a maximum exposure up to approximately 3.5 years

Recombinant Human Hyaluronidase in HyQvia makes it different from other immune globulin (IG) treatments by helping increase the dispersion and absorption of IG into the bloodstream.1

It has been shown to locally, temporarily, and reversibly modify the hyaluronan in the subcutaneous tissue, helping increase the dispersion and absorption of IG.1

  • Over the course of the efficacy and extension trials of HyQvia in ~3.5 years (2959 infusions), there were no clinically observable changes in the skin or the subcutaneous tissue1†

Permeability of the subcutaneous tissue is restored within 24 to 48 hours.1

The body's natural composition of hyaluronan.

The body naturally contains hyaluronan.1

The subQ tissue directly beneath your skin is naturally filled with hyaluronan.

Hyaluronan in the body limiting the volume of IG that can be infused.

Hyaluronan limits the volume of IG that can be infused.1

Without the Recombinant Human Hyaluronidase (Hy) in HyQvia, hyaluronan would limit the amount of immunoglobulin that can be infused into the subQ tissue.

Recombinant Human Hyaluronidase makes room for a larger volume of IG¹ in the body.

Hy makes room for a larger volume of IG.1

Hy allows a larger amount of IG to reach the subQ tissue and be absorbed into the bloodstream. That's why HyQvia can be infused monthly,* which is less frequent than other subQ IG treatments.

subQ=subcutaneous.

*Every 3 or 4 weeks.

Get answers to your questions. Talk to a representative about HyQvia.

REFERENCE

  1. HyQvia. Prescribing information. Takeda Pharmaceuticals U.S.A., Inc.; 2023.